Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 21 papers were listed this time. Here's a few in our areas of research interest:
Guillermin AL, Lloyd A, Best JH, Beth Deyoung M, Samyshkin Y, Aledort Gaebler J. Long-term cost-consequence analysis of exenatide once weekly versus sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ. 2012 Feb 28. [Epub ahead of print] PubMed PMID: 22369345.
Alzahouri K, Bahrami S, Durand-Zaleski I, Guillemin F, Roux C. Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision. Joint Bone Spine. 2012 Feb 24. [Epub ahead of print] PubMed PMID: 22366150.
Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat. 2012 Feb 24. [Epub ahead of print] PubMed PMID: 22361999.
Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer. 2012 Feb 22. [Epub ahead of print] PubMed PMID: 22359236.
